Product design and development company Cambridge Consultants has licensed its ‘reverse flow cyclone’ inhaler technology to healthcare company 3M Drug Delivery Systems.
The deal gives 3M an exclusive licence and purchase agreement for the Conix Dry Powder Inhaler (DPI).
The technology can be used in a range of devices, from single dose mass inoculation through to a multi-unit dose suitable for routine therapies, such as asthma and COPD.
According to Cambridge Consultants, the Conix technology allows the drug to be delivered deep into the lung while reducing upper airway deposition.
The device uses a ‘reverse flow cyclone’ with no moving parts or propellants. It distributes the drug throughout the inhalation, and is said to allow up to 40% increase in respirable dose compared with conventional inhalers.
David Blakey, head of drug delivery at Cambridge Consultants, said: ‘The licence marks a key stage in the evolution of Conix. We are well-known for our capabilities in device design and development, but what this deal highlights is our ability to offer a range of platform technologies and know-how that can help our clients bring solutions to market more quickly.’